2023-509488-26-00CompletedPhase 1
A study to learn how asundexian affects the amount of metformin in the blood when healthy participants take them together
Source: EU CTIS (euclinicaltrials.eu) · Last updated 31 May 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- First submitted
- 4 Apr 2024
- Start date
- 18 Jul 2024
- Lead sponsor
- Bayer AG
- EU CT number
- 2023-509488-26-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 16
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nuvisan GmbH | Neu-Ulm | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.